Sakar Healthcare has reported its audited consolidated financial results for the quarter and year ended March 31, 2026, recording a significant increase in annual net profit. The company's net profit for the fiscal year rose to 3,048.46 lakhs rupees from 1,750.20 lakhs rupees in the previous year, driven by robust operational performance and improved efficiency across its pharmaceutical manufacturing segment. For the fourth quarter, net profit stood at 1,102.43 lakhs rupees, nearly doubling from 576.11 lakhs rupees year-on-year.

FY26 Financial Performance

The annual results demonstrate strong year-on-year growth across key financial metrics. Revenue from operations for the year increased to 25,173.60 lakhs rupees from 17,758.47 lakhs rupees in the prior year, reflecting 42% YoY growth. EBITDA for FY26 stood at 6,888.82 lakhs rupees, up 39% YoY, with an EBITDA margin of 27%. The company also reported a basic earnings per share (EPS) of 13.70 rupees for the year, compared to 7.97 rupees in FY25.

Q4 Performance

For the fourth quarter ended March 31, 2026, the company delivered a strong performance with revenue climbing to 7,109.70 lakhs rupees from 5,024.18 lakhs rupees in the same quarter of the previous year, a 42% YoY increase. EBITDA for the quarter increased to 2,623.57 lakhs rupees, up 67% YoY, with EBITDA margins expanding to 37% from 31% in the corresponding prior-year quarter. Net profit for the quarter stood at 1,102.43 lakhs rupees, nearly doubling from 576.11 lakhs rupees year-on-year, with PAT margin improving to 16% from 11%.

Business Highlights

The company reported significant operational progress during Q4 and FY26, particularly within its oncology division. Key business milestones include:

• Completed over 60 business contracts with oncology products, with over 35 discussions ongoing
• Of 250 dossiers shared globally, 125 have been submitted and 12 have received Marketing Authorizations from Regulatory Authorities
• 21 of 32 developed oncology product dossiers have been shared; of which 11 dossiers have received approval, covering products including Abiraterone, Imatinib, Tamoxifen, Capecitabine, Gemcitabine, Carboplatin, Irinotecan, and Docetaxel
• Technology Transfer projects with oncology products are ongoing for Accord-Intas, Torrent-UK & Germany, Emcure, Glenmark, and Zydus, of which 4 have received site variation approvals (2 each in the UK and EU)

Management Commentary

Commenting on the results, Mr. Sanjay Shah, Managing Director, said: "Q4 marked another meaningful step forward for Sakar Healthcare, with strong year-on-year growth and improved profitability reflecting steady execution across the business. The quarter also underlined the increasing importance of oncology in our overall growth strategy, as the division continues to scale up and gradually shape the company's future growth profile. This progress is being supported by a widening product base, improving market reach, and a growing export opportunity across key markets. As approvals continue to convert into launches and commercial supplies, we believe the business is entering a stronger and more sustainable growth phase. The oncology platform, in particular, remains well placed to benefit from rising volumes, better capacity utilisation, and operating leverage as scale improves."

FY27 Outlook

Looking ahead, Sakar Healthcare anticipates FY27 to be an important year for the company, with export momentum expected to strengthen further and oncology volumes continuing to ramp up, supporting the next phase of growth. The company's focus on expanding its export footprint alongside scaling up its oncology segment is expected to further underpin its growth trajectory.

Corporate Governance

The Board of Directors approved the audited standalone and consolidated financial results at its meeting held on May 12, 2026. Additionally, the board appointed M/s. Kashyap R. Mehta & Partners as Secretarial Auditors to fill a casual vacancy. The statutory auditors, M/s. J. S. Shah & Co., issued an unmodified opinion on the financial results.

Sakar Healthcare Limited has intimated the stock exchanges of the resignation of its Secretarial Auditors, M/s. Nishant Pandya & Associates, Practising Company Secretaries, with immediate effect from the Financial Year 2025-26 onwards. The resignation letter, dated 6th May, 2026, was submitted by the firm citing personal reasons. The company made this disclosure in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of the Listing Regulations and relevant SEBI Circulars.

Resignation Details

M/s. Nishant Pandya & Associates, bearing Membership No. ACS-51005 and COP No. 22435, informed the Board of Directors of Sakar Healthcare that they are no longer associated with the company as Secretarial Auditors for the financial year 2025-26. The firm explicitly stated that there are no other material reasons for the resignation and raised no objection to the appointment of any other Secretarial Auditor by the company.

The key details of the disclosure, as submitted under Annexure 1 in compliance with Regulation 30, are outlined below:

Regulatory Compliance

The intimation was signed and submitted by Bharat Soni, Company Secretary and Compliance Officer of Sakar Healthcare Limited, on 6th May, 2026. The disclosure was addressed to the National Stock Exchange of India Limited in accordance with the applicable listing regulations. The company has requested the exchange to take note of the development in its records.